ProQR Therapeutics N.V.
Business
ProQR Therapeutics N.V. is a biotechnology company developing RNA-editing therapeutics built on its proprietary Axiomer platform to harness endogenous ADAR for precise A-to-I RNA edits. Its main products are engineered oligonucleotides called EONs and a pipeline of candidate programs including AX-0810 (NTCP), AX-2402 (MECP2), AX-1412 (B4GALT1), AX-2911 (PNPLA3) and earlier-stage discovery assets. The company’s activities are organized around research and development, intellectual property management, platform and candidate optimization, and partnerships and licensing. ProQR operates and conducts research and clinical development across Europe and the United States, leverages collaborations with biopharma partners and research funders, and uses contract research and manufacturing organizations for preclinical and clinical supply.
Summary from filing dated 2025-03-13
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-42.18M |
| Total assets | $112.76M |
| Total liabilities | $63.38M |
| Stockholders' equity | — |
| Operating cash flow | — |